Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer.

ESMO Gastrointest Oncol · 2026 · PMC13080803 · PMID 41994029

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an interesting trendno p-value reported

Thirdly, we found an interesting trend between the transcriptional activation of EMT and angiogenesis pathways and the benefit derived from cabozantinib.

also in 1,024 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.